Strengthens Leadership Team and Board with additional business development, finance and royalty management expertise SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with

SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for  Jemperli with GSK and imsidolimab with Vanda, today announced that Daniel Faga, president and chief executive officer of Anaptys, is scheduled to participate

Ruling preserves current contracted royalty rates and rejects Tesaro’s request for any royalty reduction Trial to adjudicate Anaptys’ contract claims and right to seek reversion of Jemperli against Tesaro /GSK is scheduled for July 14-17, 2026 SAN DIEGO, April 24, 2026 (GLOBE NEWSWIRE) --